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What is intracellular antibody immunity?
Antibodies or immunoglobulins (Ig) are proteins secreted into the extracellular space by B
cells to bind to pathogens and antigens. In doing so, they can prevent infection, neutralize tox-
ins, and stimulate the immune response. Antibodies achieve these effector functions by activat-
ing other serum proteins, such as complement, or by engaging antibody receptors expressed
on the surface of professional immune cells. Importantly, these processes all take place outside
cells. Antibodies are also internalized by cells and engage with receptors expressed in endoso-
mal compartments, such as the neonatal fragment crystallizable region (Fc) receptor and the
polymeric Ig receptor. These receptors have roles in recycling and transcytosis—the redistribu-
tion of antibodies back into serum or transport through the cell to specific tissue compart-
ments such as the gut epithelium or from mother to fetus. In the last decade, however, it has
been discovered that antibodies have a second life inside the cytosol, where they engage with a
specialized antibody receptor called tripartite motif-containing protein (TRIM) 21 and activate
a second line of immune defense [1].
What is TRIM21?
TRIM21 is a ubiquitously expressed, type I interferon–inducible cytosolic protein that binds
to antibodies with high affinity [2,3]; indeed, TRIM21 is the highest affinity IgG receptor in
humans [1]. Like other members of the TRIM family, TRIM21 contains a RING-type E3 ubi-
quitin ligase domain followed by a B-box domain and a coiled-coil domain that is thought to
form an antiparallel homodimer [4]. TRIM21 also contains a C-terminal PRYSPRY domain,
the 2 copies of which allow simultaneous binding of the 2 heavy-chains found in an antibody
[3]. TRIM21 binds to all 4 subclasses of IgG (IgG1, IgG2, IgG3, and IgG4) with comparable
affinities, and this binding is remarkably highly conserved, meaning that human and mouse
TRIM21 will bind to antibodies from other mammals [2]. In addition, TRIM21 has also been
shown to bind to the heavy-chains of IgA and IgM, albeit weaker than IgG [5]. This is in con-
trast to classical cell surface antibody receptors, which are completely unrelated to TRIM21
and display strong selectivity for specific antibody isotype and subclass.
What does TRIM21 do?
Antibodies don’t normally access the cytosol because they can’t pass through plasma or endo-
somal membranes. However, they are good at opsonizing (binding to) viruses in the extracel-
lular space. Viruses are obligate intracellular pathogens that have evolved specific mechanisms
to trigger endocytosis and disrupt endosomal membranes in order to gain access to cellular
machinery. An antibody-bound virus that escapes the endosomal compartment and enters the
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cytosol during infection will be met by TRIM21, which detects the virus by binding to the anti-
body Fc region. Importantly, as well as being an antibody receptor, TRIM21 is capable of cata-
lyzing ubiquitination using its RING domain [1,6]. Once TRIM21 detects an antibody-bound
virus, it becomes activated and begins synthesizing ubiquitin chains. These chains have 2 func-
tions: They cause proteasomal degradation of the virus, and they stimulate immune signaling
(Fig 1). This combination of sensor and effector responses provides both an immediate coun-
termeasure against the virus and activates an ongoing antiviral state throughout the host.
Therefore, TRIM21 provides a crucial mechanism by which non–entry blocking antibodies
deposited on the surface of viral particles can mediate a post-entry inhibition to viral replica-
tion. For instance, the humoral response to human adenovirus 5 (AdV5) predominantly
Fig 1. Schematic overview of TRIM21-mediated degradation of pathogens and proteins. Image credit: Visual Aids
Department, MRC Laboratory of Molecular Biology. TRIM21, tripartite motif-containing protein 21.
https://doi.org/10.1371/journal.ppat.1008657.g001
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generates non–entry blocking antibodies directed against the viral hexon protein [7], meaning
that AdV5 bound by this antibody can still engage cellular receptors and enter cells by endocy-
tosis [8]. Nevertheless, this non–entry blocking anti-hexon antibody has been shown to medi-
ate TRIM21-dependent post-entry neutralization of AdV5 [8].
How does TRIM21 work?
When the RING domain of TRIM21 is activated, it begins catalyzing the assembly of self-
anchored, K63-linked ubiquitin chains in conjunction with the E2 enzymes Ube2W and
Ube2N/2V2 [6]. These self-anchored K63-linked ubiquitin chains are subsequently modified
by additional ubiquitin chains with a K48-linkage [6]. TRIM21-mediated ubiquitination
results in the recruitment of proteasomes and degradation of the antibody-bound viral parti-
cles [1]. This proteasome-mediated degradation of virus-antibody complexes is a remarkably
fast process, and in the case of AdV5, it is facilitated by the cofactor AAA-ATPase valosin-con-
taining protein (VCP)/p97 and allows TRIM21 to destroy an incoming virus before it begins
replicating [1]. However, VCP is not always required for TRIM21-mediated degradation of
simpler substrates, such as IgG Fc protein expressed inside cells [9].
TRIM21-mediated antibody-dependent intracellular neutralization (ADIN) is an incredibly
efficient process; just 2 antibody molecules per adenovirus particle can be sufficient for post-
entry neutralization of adenovirus in cultured cells [10]. ADIN of nonenveloped viruses has
been demonstrated in a diverse range of cell lines from a variety of mammalian species as well
as in in vivo mouse models [8,11]. Most recently, swine TRIM21 has been shown to mediate
antiserum-dependent neutralization of the foot-and-mouth disease virus [12]. In addition to
virus neutralization, TRIM21 mediates antibody-dependent inhibition of intercellular seeding
of tau aggregates [13]. Similar to virus neutralization, the inhibition of tau seeding is both VCP
and proteasome dependent [13] (Fig 1).
When TRIM21 detects antibody-coated pathogens inside the cell, it also triggers innate
immune signaling pathways, including NF-κB, AP-1, IRF3, IRF5, and IRF7 [14]. TRIM21
can do this because the K63-linked ubiquitin chains it synthesizes are potent immune activa-
tors. Nuclear factor-κB (NF-κB) is a master regulator of innate immune signaling, and
K63-linked ubiquitin chains are sufficient for NF-κB pathway activation [15]. TRIM21 has
been shown to activate NF-κB upon infection with antibody-bound human adenovirus and
rhinovirus, feline calicivirus, and Salmonella enterica [14,16]. Importantly, TRIM21 syner-
gizes with other pattern-recognition receptors to potentiate immune sensing. When
TRIM21 causes the proteasomal degradation of an incoming virus, it exposes the viral
genome to cytosolic nucleic acid sensors. TRIM21 has been shown to reveal the genome of
adenovirus to cGAS/STING and the genome of rhinovirus to RIG-I/MAVS [16]. In primary
human macrophages, TRIM21-mediated viral genome exposure stimulates a cascade of sen-
sors ultimately leading to activation of the inflammasome, pyroptosis, and the release of IL-
1β [17]. Unlike nonimmune cells, macrophages express a variety of Fcγ receptors in
addition to TRIM21, and in these cells, the Fcγ receptors were shown to contribute to viral
neutralization by targeting antibody-virus complexes for destruction in the phagolysosome
compartment [18]. However, even in these Fcγ-expressing professional immune cells,
TRIM21 acts as an important safety mechanism to destroy any antibody-coated viruses that
escape into the cytosol, and virus neutralization is only impaired when both of these path-
ways are suppressed [17].
By targeting antibody-coated virus particles for proteasomal degradation, TRIM21-me-
diated ADIN can, in theory, generate peptide antigens for presentation on major histocompat-
ibility complex (MHC) class I molecules via the classical antigen presentation pathway. In
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professional antigen-presenting cells, the viral antigens can also be presented on MHC class II
molecules through the cross-presentation pathway. Recently, a mutated anti-adenovirus IgG
with increased affinity for TRIM21 was shown to enhance dendritic cell (DC) activation and
cytokine secretion upon infection of DCs with mutant IgG complexed adenovirus [19]. In
addition, DCs primed with mutant IgG-adenovirus complex were shown to stimulate CD8+
T-cell proliferation and cytokine release in a co-culture system [19].
One major limitation of this TRIM21-mediated ADIN mechanism is the requirement for
the virus to carry antibodies with it into the cytosol. Although this is frequently the case for
nonenveloped viruses that enter the cell by triggering receptor-mediated endocytosis, it can be
circumvented by enveloped viruses that shed their outer lipid envelope during host cell entry.
How can we exploit TRIM21?
The key feature of TRIM21-mediated intracellular antibody immunity is that TRIM21 does
not directly engage with its target but with target-bound antibodies. This explains why it
works against such a diverse range of targets including viruses, bacteria, and proteopathic
agents. Moreover, it means that TRIM21 will target for degradation any antibody-bound pro-
tein in the cytosol. This property can be exploited to carry out protein depletion in living cells
(Fig 1). In the technology Trim-Away, antibodies against endogenous cellular proteins are
delivered into cells by methods such as electroporation or microinjection [9]. The resulting
antibody-bound target is recognized by TRIM21, and the entire protein complex is degraded
by the ubiquitin-proteasome system [9]. The cross-species activity of TRIM21 is particularly
helpful here as it enables off-the-shelf antibodies raised in different mammals to be used in
degradation experiments without the need for modification [9]. Trim-Away provides an alter-
native to small interfering RNA (siRNA) and can be used in the same kind of experiments to
study protein function. However, because Trim-Away works at the protein level, it is much
faster and will remove a target protein within hours [9], rather than days as with siRNA.
Trim-Away also has 3 further benefits. First, it enables the depletion of proteins in cells that
are not amenable to standard genetic-based techniques, such as in primary cells in which active
nucleotide-sensing pathways generate unwanted inflammatory responses to DNA or RNA
transfection [20]. Indeed, Trim-Away has been used to demonstrate that NLRP3 is vital for
inflammasome formation and interleukin-1β secretion by ex vivo human monocyte–derived
macrophages [9]. Second, Trim-Away can be used in cells that are transcriptionally quiescent,
such as oocytes, in which the target protein has a long cytosolic half-life, or to acutely remove
proteins that are essential for long-term cell survival. For example, Trim-Away was used to
rapidly degrade target proteins at specific stages of cell division during oocyte meiosis [21].
Third, Trim-Away allows transcriptional pathways to be rapidly activated. For instance,
Trim-Away has been used to degrade IκB and induce NF-κB activation [9]. Although transient
selective protein degradation is a distinguishing feature of Trim-Away, it can also be used to
achieve long-lasting persistent protein knockdown by expressing nanobody-Fc fusion proteins
[9]. Expression of a nanobody-Fc fusion by mRNA transfection has been shown to allow tar-
geting of nuclear-localized proteins such as histone H2B for degradation, whereas full-length
antibodies are too large to access the nuclear compartment [9].
What next?
Understanding intracellular antibody immunity and the role of TRIM21 has potential implica-
tions for future vaccine and gene therapy design. TRIM21 was shown to be a major contribut-
ing factor for inhibiting adenoviral gene delivery in vivo in the presence of preexisting
antibody [8]. Preventing this, for instance, by using a small molecule inhibitor of TRIM21,
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could make repeated viral-based gene therapy treatments viable. Conversely, activating
TRIM21 during vaccination could help induce a more robust protective response. This is
because TRIM21-mediated proteasomal degradation of viral proteins has the potential to gen-
erate peptides for antigen presentation [19], and TRIM21 activation of innate signaling could
provide costimulatory signals for professional immune cells. Additionally, there may be ways
to expand Trim-Away from a laboratory tool to a therapeutic modality. Trim-Away has been
shown to function in living organisms and has been used to study embryogenesis in zebra
fish [22]. This was possible despite the fact that TRIM21 is naturally only found in mammals
because the ubiquitin-proteasome system that Trim-Away relies on is highly conserved across
eukaryotes. In this example, both the TRIM21 and antibody proteins were introduced by
microinjection. Therapeutic delivery of antibodies into the cells of complex living organisms is
still far off, as the same barriers that ordinarily keep antibodies outside the cell also prevent
easy delivery of protein-based drugs into the cytosol. One possible solution may be to replace
antibodies with a bispecific small molecule, such as a bispecific proteolysis-targeting chimera
(PROTAC). PROTACs recruit E3 ubiquitin ligases to degrade intracellular proteins [23], and
TRIM21 may be ideally suited for such an approach, given it already uses an intermediary mol-
ecule for target recruitment. However, such technologies require comprehensive understand-
ing of TRIM21 structure, mechanism of regulation, activation and enzymatic catalysis, which
are the subject of current and future studies.
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